BridgeMD
CELLVICROHN study: Is there a concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology to determine the microscopic inflammation at the ileal resection margins in Crohn’s ileal disease.
EU CTIS ID: 2024-517220-19-00
What this study is testing
to evaluate the intraoperative use of Cellvizio (using the CelioFlex microsonde) with an intravenous injection of fluorescein to determine the best ileal resection margins in Crohn disease.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patient ≥ 18 years old
- Patient with end-stage ileal Crohn's disease (regardless of phenotype) requiring ileocaecal resection
You likely can't join if
- - Patients with Crohn's disease operated on urgently for peritonitis
- Patient with a contraindication to the injection of fluorescein (allergy to fluorescein, severe allergy to a drug, moderate to severe renal insufficiency, hepatic insufficiency, history of cardiopulmonary disease, diabetes, concomitant treatments (in particular beta-blockers , including beta-blockers in eye drops)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.